NEW YORK (GenomeWeb) – A newly published multi-institutional cohort study has validated Epic Sciences' circulating tumor cell-based AR-V7 test, now marketed by Genomic Health as Oncotype DX AR-V7 Nucleus Detect.
NEW YORK (GenomeWeb) – A newly published multi-institutional cohort study has validated Epic Sciences' circulating tumor cell-based AR-V7 test, now marketed by Genomic Health as Oncotype DX AR-V7 Nucleus Detect.
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.